Search Results - "Monson, Kelsey"

Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma by Monson, Kelsey R, Ferguson, Robert, Handzlik, Joanna E, Xiong, Jiahan, Dagayev, Sasha, Morales, Leah, Chat, Vylyny, Bunis, Anabelle, Sreenivasaiah, Chaitra, Dolfi, Sonia, Tenney, Daniel J, Shao, Yongzhao, Osman, Iman, Weber, Jeffrey S, Kirchhoff, Tomas

“…Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant (NAT) melanoma treatments. However, ICI frequently induces severe…”
Get full text

Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort by Monson, Kelsey R, Goldberg, Mandy, Wu, Hui-Chen, Santella, Regina M, Chung, Wendy K, Terry, Mary Beth

“…Insulin-like growth factor 1 (IGF-1) and binding protein 3 (IGFBP-3) are associated with breast cancer in women at average risk of cancer. Less is known…”
Get full text

Altered salivary microbiota associated with high-sugar beverage consumption by Fan, Xiaozhou, Monson, Kelsey R., Peters, Brandilyn A., Whittington, Jennifer M., Um, Caroline Y., Oberstein, Paul E., McCullough, Marjorie L., Freedman, Neal D., Huang, Wen-Yi, Ahn, Jiyoung, Hayes, Richard B.

“…The human oral microbiome may alter oral and systemic disease risk. Consuming high sugar content beverages (HSB) can lead to caries development by altering the…”
Get full text

Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition by Ferguson, Robert, Chat, Vylyny, Morales, Leah, Simpson, Danny, Monson, Kelsey R., Cohen, Elisheva, Zusin, Sarah, Madonna, Gabriele, Capone, Mariaelena, Simeone, Ester, Pavlick, Anna, Luke, Jason J., Gajewski, Thomas F., Osman, Iman, Ascierto, Paolo, Weber, Jeffrey, Kirchhoff, Tomas

“…Immune checkpoint inhibition (ICI) has improved clinical outcomes for metastatic melanoma patients; however, 65–80% of patients treated with ICI experience…”
Get full text

Correction: Tumor immunogenomic signatures improve a prognostic model of melanoma survival by Morales, Leah, Simpson, Danny, Ferguson, Robert, Cadley, John, Esteva, Eduardo, Monson, Kelsey, Chat, Vylyny, Martinez, Carlos, Weber, Jefrey, Osman, Iman, Kirchhof, Tomas

Get full text

Tumor immunogenomic signatures improve a prognostic model of melanoma survival by Morales, Leah, Simpson, Danny, Ferguson, Robert, Cadley, John, Esteva, Eduardo, Monson, Kelsey, Chat, Vylyny, Martinez, Carlos, Weber, Jeffrey, Osman, Iman, Kirchhoff, Tomas

“…Tumor mutation burden (TMB) has been associated with melanoma immunotherapy (IT) outcomes, including survival. We explored whether combining TMB with…”
Get full text

Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes by Ibrahim, Milad, Illa-Bochaca, Irineu, Fa'ak, Faisal, Monson, Kelsey R, Ferguson, Robert, Lyu, Chen, Vega-Saenz de Miera, Eleazar, Johannet, Paul, Chou, Margaret, Mastroianni, Justin, Darvishian, Farbod, Kirchhoff, Tomas, Zhong, Judy, Krogsgaard, Michelle, Osman, Iman

“…We previously reported a higher incidence of a pathogenic germline variant in the kinase insert domain receptor (KDR) in melanoma patients compared to the…”
Get full text

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma by Khushalani, Nikhil I, Vassallo, Melinda, Goldberg, Judith D, Eroglu, Zeynep, Kim, Younchul, Cao, Biwei, Ferguson, Robert, Monson, Kelsey R, Kirchhoff, Tomas, Amato, Carol M, Burke, Paulo, Strange, Ann, Monk, Emily, Gibney, Geoffrey Thomas, Kudchadkar, Ragini, Markowitz, Joseph, Brohl, Andrew S, Pavlick, Anna, Richards, Alison, Woods, David M, Weber, Jeffrey

“…BackgroundAdjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years…”
Get full text

Elevated dietary carbohydrate and glycemic intake associate with an altered oral microbial ecosystem in two large U.S. cohorts by Monson, Kelsey R, Peters, Brandilyn A, Usyk, Mykhaylo, Um, Caroline Y, Oberstein, Paul E, McCullough, Marjorie L, Purdue, Mark P, Freedman, Neal D, Hayes, Richard B, Ahn, Jiyoung

“…The human oral microbiome is associated with chronic diseases including cancer. However, our understanding of its relationship with diet is limited. We…”
Get full text

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel by Smyth, Lillian M., Monson, Kelsey R., Jhaveri, Komal, Drilon, Alexander, Li, Bob T., Abida, Wassim, Iyer, Gopa, Gerecitano, John F., Gounder, Mrinal, Harding, James J., Voss, Martin H., Makker, Vicky, Ho, Alan L., Razavi, Pedram, Iasonos, Alexia, Bialer, Philip, Lacouture, Mario E., Teitcher, Jerrold B., Erinjeri, Joseph P., Katabi, Nora, Fury, Matthew G., Hyman, David M.

“…Summary Purpose We previously reported the phase I dose escalation study of buparlisib, a pan-class 1A PI3K inhibitor, combined with platinum/taxane-based…”
Get full text

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors by Hyman, David M., Snyder, Alexandra E., Carvajal, Richard D., Gerecitano, John F., Voss, Martin H., Ho, Alan L., Konner, Jason, Winkelmann, Jennifer L., Stasi, Megan A., Monson, Kelsey R., Iasonos, Alexia, Spriggs, David R., Bialer, Philip, Lacouture, Mario E., Teitcher, Jerrold B., Katabi, Nora, Fury, Matthew G.

“…Purpose Phosphatidylinositol-3-kinase I (PI3K) inhibition sensitizes a wide range of cancer cell lines to platinum/taxane-based chemotherapy. This phase I…”
Get full text

Distinct genetic and phenotypic characteristics of not otherwise specified (NOS) melanoma by Goldberger, Clara, Fa'ak, Faisal, Lyu, Chen, Shapiro, Richard, Berman, Russell S., Friedman, Erica, Lee, Ann Yeelin, Bayraktar, Erol, Jour, George, Monson, Kelsey, Ferguson, Robert, Kirchhoff, Tomas, Zhong, Hua, Osman, Iman

“…e21571 Background: We previously reported on the biological relevance of melanoma histologic subtypes (Lattanzi et al, JNCI 2019). However, a substantial…”
Get full text

Novel blood-based biomarker predicting severe toxicity in melanoma anti-CTLA-4 immunotherapy treatment by Chat, Vylyny, Ferguson, Robert, Morales, Leah, Monson, Kelsey, Esteva, Eduardo, Moran, Una, Pavlick, Anna C., Ascierto, Paolo Antonio, Osman, Iman, Weber, Jeffrey S., Kirchhoff, Tomas

“…Abstract only 3077 Background: Immune checkpoint inhibition (ICI) has improved clinical outcomes of metastatic melanoma (MM). However, 65-80% of treated…”
Get full text

Abstract 1107: Co-treatment with a C1B5 domain peptide of protein kinase Cγ and a low dose of gemcitabine effectively inhibited pancreatic cancer growth in mouse peritoneal cavity by Zulbaran, Alejandro, Monson, Kelsey, Ishiguro, Susumu, Kawabata, Atsushi, Uppalapati, Deepthi, Ohta, Naomi, Tamura, Masaaki

“…Although the gemcitabine is an effective chemotherapeutic agent for pancreatic cancer, unacceptable side effects often accompany. Since we have previously…”
Get full text

Co-treatment with a C1B5 peptide of protein kinase Cγ and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation by Ishiguro, Susumu, Kawabata, Atsushi, Zulbaran-Rojas, Alejandro, Monson, Kelsey, Uppalapati, Deepthi, Ohta, Naomi, Inui, Makoto, Pappas, Charalampos G., Tzakos, Andreas G., Tamura, Masaaki

“…Although gemcitabine is an effective chemotherapeutic for pancreatic cancer, severe side effects often accompany its use. Since we have discovered that locally…”
Get full text

Abstract 1185: Novel association of an autoimmune-related axis and anti-CTLA-4-based toxicities in adjuvant immunotherapy-treated melanoma patients by Monson, Kelsey R., Ferguson, Robert, Handzlik, Joanna, Xiong, Jiahan, Dagayev, Sasha, Morales, Leah, Chat, Vylyny, Bunis, Anabelle, Sreenivasaiah, Chaitra, Dolfi, Sonia, Tenney, Daniel, Osman, Iman, Weber, Jeffrey, Kirchhoff, Tomas

“…Intro: Immune checkpoint inhibition (ICI) for metastatic unresectable melanoma has markedly improved survival, and has shown benefit as adjuvant (AT) and…”
Get full text